TransMedics Group Inc (FRA:8T8)
€ 75.94 1.86 (2.51%) Market Cap: 2.56 Bil Enterprise Value: 2.73 Bil PE Ratio: 90.32 PB Ratio: 13.57 GF Score: 76/100

Q2 2024 Transmedics Group Inc Earnings Call Transcript

Jul 31, 2024 / 08:30PM GMT
Release Date Price: €125.35 (-1.80%)

Key Points

Positve
  • TransMedics Group Inc (TMDX) reported significant revenue growth of 118% year-over-year and 18% sequentially, reaching $114.3 million in Q2 2024.
  • The company achieved its first positive free cash flow quarter, generating approximately $2 million despite purchasing a new aircraft.
  • TransMedics expanded its aviation fleet to 17 aircraft, enhancing its transplant logistics network to meet growing demand.
  • The company maintained profitability with a GAAP operating profit of $12.5 million, representing 11% of total revenue.
  • TransMedics increased its annual full-year revenue guidance to between $425 million to $445 million, indicating strong growth expectations.
Negative
  • Gross margins slightly decreased to 61% in Q2 2024 from 62% in Q1 2024, with expectations of further fluctuations in the coming quarters.
  • The company anticipates some fluctuation in free cash flow over the next 12 to 18 months due to continued heavy investment in business and product pipelines.
  • Service margin declined primarily due to significant investment in pilot hiring and training, as well as aviation maintenance.
  • There is potential for temporary limitations in logistics revenue growth in H2 2024 due to scheduled aircraft maintenance.
  • TransMedics faces challenges in maintaining operational efficiency as it scales its air fleet and ground operations.
Operator

Good afternoon, and welcome to the TransMedics second-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Laine Morgan from the Gilmartin Group for a few introductory comments.

Laine Morgan
Gilmartin Group LLC - IR

Thank you, operator. Earlier today, TransMedics released financial results for the quarter ended June 30, 2024. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that management will make statements during this call, including during the question-and-answer portion of the call, that include forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to the expectations or predictions of future events, results or performance are forward-looking statements.

All forward-looking statements, including, without limitation, our examination of operating trends, the potential commercial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot